Relmada Therapeutics Analyst Ratings
Relmada Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/23/2023 | 110.08% | SVB Leerink | $42 → $10 | Maintains | Outperform |
| 10/14/2022 | 68.07% | Goldman Sachs | → $8 | Downgrades | Buy → Neutral |
| 10/14/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 10/13/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/23/2022 | 1601.68% | Goldman Sachs | $49 → $81 | Maintains | Buy |
| 09/06/2022 | 1160.5% | Guggenheim | $50 → $60 | Maintains | Buy |
| 05/09/2022 | 1244.54% | Oppenheimer | $75 → $64 | Maintains | Outperform |
| 03/24/2022 | 1013.45% | Goldman Sachs | $69 → $53 | Maintains | Buy |
| 12/20/2021 | 782.35% | SVB Leerink | $50 → $42 | Maintains | Outperform |
| 11/18/2021 | 950.42% | Mizuho | → $50 | Initiates Coverage On | → Buy |
| 10/28/2020 | 740.34% | Goldman Sachs | $69 → $40 | Downgrades | Buy → Neutral |
| 05/04/2020 | 1475.63% | SunTrust Robinson Humphrey | → $75 | Initiates Coverage On | → Buy |
| 04/21/2020 | 1223.53% | Goldman Sachs | → $63 | Initiates Coverage On | → Buy |
| 01/27/2020 | 1475.63% | Jefferies | → $75 | Initiates Coverage On | → Buy |
| 12/16/2019 | 1244.54% | Guggenheim | → $64 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年1月23日 | 110.08% | SVB Leerink | $42→$10 | 維護 | 跑贏大盤 |
| 10/14/2022 | 68.07% | 高盛 | →$8 | 評級下調 | 購買→中性 |
| 10/14/2022 | - | 古根海姆 | 評級下調 | 購買→中性 | |
| 10/13/2022 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 09/23/2022 | 1601.68% | 高盛 | $49→$81 | 維護 | 買 |
| 09/06/2022 | 1160.5% | 古根海姆 | $50→$60 | 維護 | 買 |
| 05/09/2022 | 1244.54% | 奧本海默 | $75→$64 | 維護 | 跑贏大盤 |
| 03/24/2022 | 1013.45% | 高盛 | $69→$53 | 維護 | 買 |
| 12/20/2021 | 782.35% | SVB Leerink | $50→$42 | 維護 | 跑贏大盤 |
| 2021年11月18日 | 950.42% | 瑞穗 | →$50 | 開始承保 | →購買 |
| 10/28/2020 | 740.34% | 高盛 | $69→$40 | 評級下調 | 購買→中性 |
| 05/04/2020 | 1475.63% | SunTrust Robinson Humphrey | →$75 | 開始承保 | →購買 |
| 04/21/2020 | 1223.53% | 高盛 | →$63 | 開始承保 | →購買 |
| 2020/01/27 | 1475.63% | 傑富瑞 | →$75 | 開始承保 | →購買 |
| 2019年12月16日 | 1244.54% | 古根海姆 | →$64 | 開始承保 | →購買 |
What is the target price for Relmada Therapeutics (RLMD)?
瑞馬達治療公司(RLMD)的目標價格是多少？
The latest price target for Relmada Therapeutics (NASDAQ: RLMD) was reported by SVB Leerink on January 23, 2023. The analyst firm set a price target for $10.00 expecting RLMD to rise to within 12 months (a possible 110.08% upside). 8 analyst firms have reported ratings in the last year.
SVB Leerink於2023年1月23日報道了瑞瑪達治療公司(納斯達克代碼：RLMD)的最新目標價。這家分析公司將目標價定為10美元，預計RLMD將在12個月內升至(可能上漲110.08%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Relmada Therapeutics (RLMD)?
瑞馬達治療公司(RLMD)的最新分析師評級是什麼？
The latest analyst rating for Relmada Therapeutics (NASDAQ: RLMD) was provided by SVB Leerink, and Relmada Therapeutics maintained their outperform rating.
瑞馬達治療公司(納斯達克代碼：RLMD)的最新分析師評級由SVB Leerink提供，瑞馬達治療公司維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?
Relmada治療公司(RLMD)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Relmada Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Relmada治療公司的上一次評級是在2023年1月23日提交的，所以你應該預計下一次評級將在2024年1月23日左右的某個時候提供。
Is the Analyst Rating Relmada Therapeutics (RLMD) correct?
分析師對Relmada Treeutics(RLMD)的評級正確嗎？
While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a maintained with a price target of $42.00 to $10.00. The current price Relmada Therapeutics (RLMD) is trading at is $4.76, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Relmada Treeutics(RLMD)評級保持不變，目標價在42.00美元至10.00美元之間。Relmada治療公司(RLMD)目前的交易價格為4.76美元，超出了分析師的預測範圍。